

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

July 18, 2024

Martin Brenner Chief Executive Officer and Chief Scientific Officer iBio, Inc. 11750 Sorrento Valley Road, Suite 200 San Diego, CA 92121

Re: iBio, Inc.

Registration Statement on Form S-3

Filed July 3, 2024 File No. 333-280680

Dear Martin Brenner:

We have conducted a limited review of your registration statement and have the following comments.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-3

Prospectus Summary Overview, page 1

- 1. Please revise your Prospectus Summary Overview to provide context and balance to your discussion of your platform and AI-engine. For instance, please highlight, if true, that you have a limited operating history developing vaccines and therapeutics, that you have not conducted clinical trials on any product candidates, and that there is a risk that you may be unsuccessful in developing or commercializing any product candidates.
- 2. Please revise to explain your basis for making all performance and leadership claims, including the following ones:
 - Your belief that you "lead the field with (y)our patented AI-engine uncovering 'hard to develop' molecules;"
 - Your "groundbreaking EngageTxTM technology enables (you) to target bi-specific molecules;"

July 18, 2024 Page 2

- Your ability to "navigate sequence diversity and promote Human-Cyno cross reactivity while mitigating cytokine release;"
- Your "unparalleled epitope engine stands out by allowing the ability to target select regions of a protein, potentially removing the lengthy trial and error out of mAb discovery;"
- Your AI-engine is expected to "increase the probability of success."

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

Please contact Daniel Crawford at 202-551-7767 or Joe McCann at 202-551-6262 with any other questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Melissa Palat Murawsky, Esq.